AbbVie (NYSE:ABBV) Updates Q2 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its second quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.570-3.610 for the period, compared to the consensus estimate of 3.770. The company issued revenue guidance of -. AbbVie also updated its FY 2026 guidance to 13.910-14.110 EPS.

AbbVie Stock Performance

Shares of AbbVie stock opened at $254.71 on Wednesday. The firm has a 50-day moving average of $222.39 and a 200-day moving average of $220.69. The stock has a market cap of $450.02 billion, a PE ratio of 125.47, a PEG ratio of 0.84 and a beta of 0.30. AbbVie has a 52-week low of $184.63 and a 52-week high of $261.64.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the company earned $2.46 EPS. AbbVie’s revenue was up 12.4% compared to the same quarter last year. Equities research analysts predict that AbbVie will post 14.28 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is 340.89%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Thursday, April 30th. Morgan Stanley lifted their price objective on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $298.00 price objective on shares of AbbVie in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $256.67.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved AbbVie’s TEPKINLY combination for relapsed or refractory follicular lymphoma, expanding the company’s oncology franchise and potentially adding a new growth driver. Article Title
• Positive Sentiment: Phase 3 data showed strong efficacy for TEPKINLY + R2, including statistically significant progression-free survival and response rate improvements, which supports the commercial outlook for the drug. Article Title
• Neutral Sentiment: AbbVie also received analyst attention and favorable dividend-stock mentions, but these items are more sentiment-driven and do not materially change the near-term fundamental story. Article Title
• Negative Sentiment: AbbVie’s updated 2026 and second-quarter EPS guidance came in below consensus, which could weigh on investor sentiment despite the positive pipeline news. Guidance update

Institutional Trading of AbbVie

Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Raymond James Financial Inc. boosted its stake in AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. Amundi grew its holdings in shares of AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after buying an additional 1,414,621 shares in the last quarter. State Street Corp raised its position in shares of AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after buying an additional 1,119,274 shares during the last quarter. Finally, First Trust Advisors LP raised its position in shares of AbbVie by 170.2% in the fourth quarter. First Trust Advisors LP now owns 1,336,498 shares of the company’s stock valued at $305,377,000 after buying an additional 841,947 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.